Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors
Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors
Recruiting · NCT06651593 · Registry updated 2026-07-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors | Solid Tumors | Recruiting | Phase 2 | 2026-07-09 | NCT06651593 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| M.D. Anderson Cancer Center | 1145 |
| Regeneron Pharmaceuticals | 238 |
| Sanofi | 254 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| MD Anderson Cancer Center | Houston | United States | 589 |